Last reviewed · How we verify
PD-1 Antibody, chidamide, lenalidomide and etoposide
PD-1 Antibody, chidamide, lenalidomide and etoposide is a Small molecule drug developed by Mingzhi Zhang. It is currently FDA-approved.
At a glance
| Generic name | PD-1 Antibody, chidamide, lenalidomide and etoposide |
|---|---|
| Sponsor | Mingzhi Zhang |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 Antibody, chidamide, lenalidomide and etoposide CI brief — competitive landscape report
- PD-1 Antibody, chidamide, lenalidomide and etoposide updates RSS · CI watch RSS
- Mingzhi Zhang portfolio CI
Frequently asked questions about PD-1 Antibody, chidamide, lenalidomide and etoposide
What is PD-1 Antibody, chidamide, lenalidomide and etoposide?
PD-1 Antibody, chidamide, lenalidomide and etoposide is a Small molecule drug developed by Mingzhi Zhang.
Who makes PD-1 Antibody, chidamide, lenalidomide and etoposide?
PD-1 Antibody, chidamide, lenalidomide and etoposide is developed and marketed by Mingzhi Zhang (see full Mingzhi Zhang pipeline at /company/mingzhi-zhang).
What development phase is PD-1 Antibody, chidamide, lenalidomide and etoposide in?
PD-1 Antibody, chidamide, lenalidomide and etoposide is FDA-approved (marketed).